News
95.6% Retention Rate Achieved in Phase 3 Type 2 Diabetes & Obesity Trial
In the rapidly evolving landscape of metabolic health, the demand for high-quality, reliable data in Type 2 Diabetes (T2DM) and obesity trials has never been greater. DelRicht Research has proven to be a cornerstone partner for T2DM and obesity clinical trials. By combining aggressive recruitment strategies with a streamlined operational...
DelRicht Research Enrolls 159.49% of Expected Goal in Phase 3 Obesity Trial
As the clinical focus shifts toward the growing complexities of chronic weight management, the demand for high-quality, reliable data in obesity trials has never been greater. DelRicht Research has proven to be a cornerstone partner for sponsors navigating the complexities of chronic weight management and its associated comorbidities. By combining...
Delivering Expertise and Enrollment Success in Cardiometabolic Research
Cardiometabolic research stands at the intersection of some of the most complex and prevalent health challenges of our time. From the rising tide of obesity and metabolic-associated steatohepatitis (MASH) to the persistent burden of Type 2 Diabetes Mellitus (T2DM) and hypertension, trials in this space require more than just patient...
Dr. Patrick Dennis Contributes to Herpes Zoster Research Published in CID
NEW ORLEANS, LA – Exciting progress continues to emerge in the ongoing effort to advance Herpes Zoster vaccine research, particularly in co-administration of RSVPreF3 and RZV and how it could improve vaccine coverage and reduce the number of vaccination visits for adults older than 50 years of age. Among the...
DelRicht Enrolls 126% of Expected Enrollment in a Phase 3 Pneumococcal Vaccine Trial
Selected as a participating site network for a Phase 3 Pneumococcal Vaccine trial, DelRicht Research was entrusted with enrolling healthy, pneumococcal-naïve adults across two specialized sites. From challenges including strict “pneumococcal-naïve” verification requirements for older populations and the technical barriers of 24-hour eDiary windows, DelRicht Research delivered through refined intake...
Proven Success in Psoriasis Trials: The DelRicht Difference
As the psoriasis landscape shifts toward targeted biologics and innovative topicals, DelRicht Research offers sponsors a premier partnership built on operational excellence. With 14 psoriasis trials completed, 130+ participants enrolled, and 8 experienced sites nationwide, our embedded network delivers high-quality data and rapid enrollment for even the most complex dermatology...
Dr. Robert Springer Contributes to COVID-19 Vaccine Research Presented at ESCMID Global 2026
ATLANTA, GA – Exciting progress continues to emerge in the ongoing effort to advance COVID-19 vaccine research, particularly as new variants reshape the global health landscape. A recent poster presentation, “Effectiveness and Safety of Variant-Updated COVID-19 Vaccines,” highlights the importance of continuously evolving vaccine strategies to maintain protection and improve...
Top 3 Enroller Studywide: Achieving 267% of the Goal in Phase 2 Obesity & T2DM Trial
DelRicht Research is proud to highlight the exceptional performance of Dr. Patrick Dennis and his team at Touro Medical Center in New Orleans, LA, whose site achieved top-tier enrollment results in a Phase 2 clinical trial focused on obesity and Type 2 diabetes (T2DM). Their ability to rapidly activate, enroll,...
What Happens When a Trial is Cancelled or Delayed: The Impact on Sites & Site Networks
Clinical research has always evolved through change. New science, shifting priorities, and even the difficult decisions to pause or cancel a study are part of the process that propels medicine forward. Recent insights from GlobalData show that roughly 4.7 percent of registered clinical trials are terminated, most often for reasons...
Dr. Patrick Dennis Featured as an Author on Recent Phase 2 Hypertension Manuscript
Uncontrolled hypertension remains a significant public health challenge, affecting millions of adults worldwide and increasing the risk of heart disease, stroke, and kidney failure. A recent publication, “Efficacy of Tonlamarsen in Patients with Uncontrolled Hypertension: The KARDINAL Phase 2 Randomized Clinical Trial,” provides important insight into a novel approach to...
